Compare Heron Therapeutics Inc (HRTX) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kinross Gold Corporation — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Kinross Gold Corporation trades at $23.06 (market cap $26.63B). The key difference: Kinross Gold Corporation is far larger — about 291.2× Heron Therapeutics Inc's market cap, and Kinross Gold Corporation pays a 0.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | KGC | |
|---|---|---|
Market Cap | $91.46M | $26.63B |
Sector | Health | Basic Materials |
52-Week High | $1.96 | $38.06 |
52-Week Low | $0.39 | $15.42 |
Enterprise Value | $189.36M | $25.18B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Kinross Gold (KGC) trades at $22.65, up 0.35% with strong fundamentals including 35.99% net margin and 35.15% ROE. The stock shows bearish technical signals despite consistent earnings beats and analyst consensus of $37.20 price target. Recent cash flow growth from $259M in 2024 to $1.13B in 2025 supports dividend payments and exploration projects.
KGC presents value opportunity with P/E of 9.6x below industry averages, though technical weakness and gold price volatility pose risks. Production growth to 2.3M+ ounces by 2028 and net cash position provide upside catalysts if gold prices stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
